Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
coBRIM: Cobimetinib + Vemurafenib in BRAF-mutated Melanoma
NCT01689519Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2013
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of cobimetinib in melanoma, sponsored by Roche. Started Jan 2013; status: completed.
02
Drugs
cobimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01689519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01689519.